logo
Plus   Neg
Share
Email

Stock Watch: Agios Pharma Rises On Positive Cholangiocarcinoma Trial Data

Shares of Agios Pharmaceuticals Inc. (AGIO) rose more than 18% in extended trading on Wednesday, following positive results from its global phase III trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation.

Cholangiocarcinoma is a group of cancers that begin in the bile ducts. (Source: NIH). Advanced cholangiocarcinoma is a life-threatening disease with no currently approved treatment options.

In the phase III trial, dubbed ClarIDHy, treatment with TIBSOVO demonstrated a statistically significant improvement in progression-free survival compared with patients who received placebo.

TIBSOVO was approved by the FDA for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation last July. The drug generated $13.84 million of net product revenue from U.S. sales of TIBSOVO in 2018.

The Company plans to submit a supplemental new drug application for TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.

AGIO closed Wednesday's trading at $47.35, down 1.00%. In after-hours, the stock was up 18.80% to $56.25.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A flaw in new iPhone operating system iOS 13, which is released by Apple on Thursday, exposes contact details stored in iPhones without requiring a passcode or biometric identification. Apple has known about the flaw since July, according to CNN business report quoting a person who reported the bug to Apple. Chinese electronics giant Huawei on Thursday launched its latest flagship smartphone range the Mate 30. Huawei unveiled the Huawei Mate 30 and Mate 30 Pro at an event in Munich. The new phones boasts of professional-grade cameras that competes directly with Apple's new iPhone 11 and iPhone 11 Pro... Schwartz Brothers Bakery of Seattle, Washington recalled 24 units of lemon dessert bars as it may contain undeclared egg. The products have a sell by date of September 21, 2019. The company issued the recall after it found that some of the Lemon Pound Cake was mislabeled as Lemon Dessert Bars. While the Lemon Pound Cake contains egg, the Lemon Dessert Bars label does not declare egg.